Trial Profile
Safety and efficacy of reduced-intensity myeloablative conditioning regimen with fludarabine and intravenous busulfan for hematological malignancies
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- 29 Oct 2011 New trial record